Quick Answer
Enliven Therapeutics, Inc. reported Diluted EPS of $1.83 per share (loss) for fiscal year 2025.
Enliven Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.83 | +3.2% |
| 2024 | -$1.89 | +6.0% |
| 2023 | -$2.01 | +83.3% |
| 2022 | -$12.05 | -408.4% |
| 2021 | -$2.37 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.32 | +33.3% | +34.7% |
| June 30, 2025 | -$0.49 | -19.5% | +14.0% |
| March 31, 2025 | -$0.57 | -5.6% | -18.7% |
| September 30, 2024 | -$0.48 | +5.9% | -17.1% |
| June 30, 2024 | -$0.41 | +0.0% | +24.1% |
| March 31, 2024 | -$0.54 | +32.5% | -5.9% |
| September 30, 2023 | -$0.51 | +84.4% | -24.4% |
| June 30, 2023 | -$0.41 | +85.7% | +48.8% |
- Enliven Therapeutics, Inc. showed an increase of +3.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Enliven Therapeutics, Inc.’s diluted eps has grown by 22.8% (from $2.37 per share (loss) to $1.83 per share (loss)).
- The most recent figure is from Enliven Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: